Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gibb

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
BMC Public Health|July 30, 2021
Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi: a secondary analysis of TRACT trial dataRoisin Connon, Elizabeth C George, Peter Olupot-Olupot, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Science Translational Medicine|April 5, 2019
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activationClaire D Bourke, Ethan K Gough, Godfrey Pimundu, et al.
The Lancet. Global Health|September 21, 2019
Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trialKathryn Maitland, Peter Olupot-Olupot, Sarah Kiguli, et al.
Plos Medicine|January 31, 2018
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study, Ali Judd, Elizabeth Chappell, et al.
The Lancet. Child & Adolescent Health|August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.
The Journal of Infectious Diseases|August 2, 2025
Brain imaging and whole blood targeted transcriptomic analyses to characterise cerebral infarctions in children with tuberculous meningitisJulie Huynh, Pieter M Pretorius, Wajanat Jan, et al.
BMJ Open|April 3, 2025
Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitisJulie Huynh, Chishala Chabala, Suvasini Sharma, et al.
Journal of the International AIDS Society|September 28, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trialLinda Namutebi Barlow-Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
BMC Public Health|July 30, 2021
Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi: a secondary analysis of TRACT trial dataRoisin Connon, Elizabeth C George, Peter Olupot-Olupot, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
Science Translational Medicine|April 5, 2019
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activationClaire D Bourke, Ethan K Gough, Godfrey Pimundu, et al.
The Lancet. Global Health|September 21, 2019
Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trialKathryn Maitland, Peter Olupot-Olupot, Sarah Kiguli, et al.
Plos Medicine|January 31, 2018
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study, Ali Judd, Elizabeth Chappell, et al.
The Lancet. Child & Adolescent Health|August 10, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Adeodata R Kekitiinwa, et al.
The Journal of Infectious Diseases|August 2, 2025
Brain imaging and whole blood targeted transcriptomic analyses to characterise cerebral infarctions in children with tuberculous meningitisJulie Huynh, Pieter M Pretorius, Wajanat Jan, et al.
BMJ Open|April 3, 2025
Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitisJulie Huynh, Chishala Chabala, Suvasini Sharma, et al.
Journal of the International AIDS Society|September 28, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trialLinda Namutebi Barlow-Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, et al.
Pageof 37